Issue highlights—July 2023.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 277, doi. 10.1002/cyto.b.22138
- By:
- Publication type:
- Article
Works matching IS 15524949 AND DT 2023 AND VI 104 AND IP 4
Results: 8
1
2
Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 279, doi. 10.1002/cyto.b.22120
- By:
- Publication type:
- Article
3
The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 311, doi. 10.1002/cyto.b.22118
- By:
- Publication type:
- Article
4
CD19 negative diffuse large B‐cell lymphoma presenting in leukemic phase.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 331, doi. 10.1002/cyto.b.22109
- By:
- Publication type:
- Article
5
Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemia.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 319, doi. 10.1002/cyto.b.22106
- By:
- Publication type:
- Article
6
Circulating CD22+/CD19−/CD24− progenitors and CD22+/CD19+/CD24− mature B cells: Diagnostic pitfalls for minimal residual disease detection in B‐lymphoblastic leukemia.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 294, doi. 10.1002/cyto.b.22104
- By:
- Publication type:
- Article
7
Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real‐world practice.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 304, doi. 10.1002/cyto.b.22100
- By:
- Publication type:
- Article
8
Issue Information.
- Published in:
- Cytometry. Part B, 2023, v. 104, n. 4, p. 271, doi. 10.1002/cyto.b.22076
- Publication type:
- Article